Canaccord Genuity Lifts CareDx Price Target to $80 From $65
Canaccord Genuity raised its CareDx price target to $80 from $65 and kept a Buy rating, according to Dow Jones Newswires.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Canaccord Genuity analysts increased their price target on CareDx shares to $80 from $65 previously. The Buy rating was maintained, Dow Jones Newswires reported, citing Benzinga ratings data.
why it matters
A target increase reflects a more optimistic analyst view of the stock, but it does not by itself change the company's reported financial results. Such moves can influence investor sentiment in the short term.
tags
instruments
sources
- CareDx Price Target Raised to $80.00/Share From $65.00 by Canaccord Genuity — Dow Jones Newswires, 19 October 2026 at 13:13 UTC
- Natera Price Target Raised to $500.00/Share From $375.00 by Canaccord Genuity — Dow Jones Newswires, 19 October 2026 at 13:19 UTC
- Exagen Price Target Raised to $11.00/Share From $9.00 by Canaccord Genuity — Dow Jones Newswires, 19 October 2026 at 13:26 UTC
- Repligen Price Target Raised to $180.00/Share From $145.00 by Canaccord Genuity — Dow Jones Newswires, 19 October 2026 at 13:22 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗